Press release - 13/06/2024 Position of the cell nucleus affects epigenetics and therefore gene activity and cell function Depending on whether the cell nucleus of an epithelial cell is located on the outer or inner side of the tissue, the genome is more or less acetylated - genes can therefore be translated easier or harder. Scientists from the German Cancer Research Center (DKFZ) have demonstrated this for the first time in the development of the Drosophila wing. https://www.gesundheitsindustrie-bw.de/en/article/press-release/position-cell-nucleus-affects-epigenetics-and-therefore-gene-activity-and-cell-function
Press release - 15/11/2024 Selenium proteins as a possible new target for cancer research An important enzyme helps the body produce selenium proteins – this discovery could open up new strategies for treating cancer in children. This has been published by scientists from the University of Würzburg, the University Sao Paolo, the German Cancer Research Center (DKFZ) and the Heidelberg Stem Cell Institute HI-STEM*.https://www.gesundheitsindustrie-bw.de/en/article/press-release/selenium-proteins-possible-new-target-cancer-research
Press release - 03/01/2025 New approaches against metastatic breast cancer: mini-tumors from circulating cancer cells Tumor cells circulating in the blood are the "germ cells" of breast cancer metastases. They are rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the DKFZ, the Heidelberg Stem Cell Institute HI-STEM and the NCT Heidelberg has now succeeded for the first time in cultivating stable tumor organoids directly from blood samples of breast cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approaches-against-metastatic-breast-cancer-mini-tumors-circulating-cancer-cells
Dossier - 05/08/2013 Progress expands bioethical boundaries Bioethics is a rich and continually evolving field. In the broadest sense, bioethics relates to the way human individuals treat any form of life. The issue of whether human beings have the right to do whatever they want goes way back. Rapid progress in genetic engineering and cell biology means that it is necessary to look at certain issues in a new way and recognise that not everything that is technically feasible should actually be carried out.https://www.gesundheitsindustrie-bw.de/en/article/dossier/progress-expands-bioethical-boundaries
Photon-counting technology - 01/02/2023 PC3 consortium: innovative computed tomography for Baden-Württemberg The University Hospitals of Freiburg, Tübingen and Mannheim have been cooperating with each other since 2021 to test new types of computed tomography devices. With the help of photon-counting technology, the aim is not only to improve patient care, but also to encourage local companies to develop downstream data processing technologies.https://www.gesundheitsindustrie-bw.de/en/article/news/pc3-consortium-innovative-computed-tomography-baden-wuerttemberg
Microstructure Technology - 17/07/2020 An electronic nose for many applications Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…https://www.gesundheitsindustrie-bw.de/en/article/news/electronic-nose-many-applications
TGU Varimol - 24/07/2020 Click chemistry for new medical procedures Using a simple molecular click process, biochemists have been able to connect ring-shaped molecules with each other and couple therapeutically active substances to these molecules. Drugs can thus be specifically delivered to diseased cells and used for imaging processes or biosensors. The Stuttgart-based start-up Varimol is using this new technology to provide its customers with tailored applications that are as simple to use as a kit.https://www.gesundheitsindustrie-bw.de/en/article/news/click-chemistry-new-medical-procedures
Assay to support the diagnosis of autoimmune diseases - 22/06/2022 Tracking down pathogenic immune complexes Soluble complexes of antibodies and their target structures circulating in the blood can trigger serious systemic inflammations. Dr. Philipp Kolb and Haizhang Chen from the Institute of Virology at the Freiburg University Medical Centre have developed a sensitive, cell-based test system for detecting these immune complexes. The system can be used to diagnose systemic autoimmune diseases, and also severe cases of COVID-19.https://www.gesundheitsindustrie-bw.de/en/article/news/tracking-down-pathogenic-immune-complexes
Neurodegenerative diseases - 12/12/2022 Blood-based biomarkers allow the early prediction of Alzheimer's risks Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.https://www.gesundheitsindustrie-bw.de/en/article/news/blood-based-biomarkers-allow-early-prediction-alzheimers-risks
Pipetting robot for academic research - 28/08/2024 goodBot GmbH: a third arm for researchers Repetitive tasks that researchers have to conduct in the lab tend to be tiring and often lead to errors. Precise pipetting is crucial for achieving reproducible results. Automation is underrepresented in research labs and existing pipetting robots are unsuitable for scientists. This is why Dr. Julius Wiener, Tobias Zundel and Oliver Brunner decided to found the company goodBot GmbH and develop a pipetting robot tailored to academic research.https://www.gesundheitsindustrie-bw.de/en/article/news/goodbot-gmbh-third-arm-researchers
Press release - 04/12/2024 Joint research in key technologies: NMI and KIT sign cooperation agreement The NMI Natural and Medical Sciences Institute and the Karlsruhe Institute of Technology (KIT) have signed a groundbreaking cooperation agreement. This partnership combines the expertise of both institutions in the fields of production and characterization of materials for biological systems and energy storage as well as the application of statistical methods in medicine.https://www.gesundheitsindustrie-bw.de/en/article/press-release/joint-research-key-technologies-nmi-and-kit-sign-cooperation-agreement
Article - 22/10/2019 Using CAR T cells for treating cancer After successes in the treatment of advanced blood cancers, CAR T-cell immunotherapy has become a major beacon of hope in oncology. The first therapies have received regulatory approval. Despite their success, these immunotherapies can have serious side effects. The company AVA Lifescience develops antibodies with high tumour specificity to use as the basis for effective precision-guided CAR T-cell therapies that are better tolerated by patients.https://www.gesundheitsindustrie-bw.de/en/article/news/using-car-t-cells-for-treating-cancer
Development of the genomDE genome database - 04/12/2020 Whole genome sequencing for diagnosing rare diseases Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…https://www.gesundheitsindustrie-bw.de/en/article/news/whole-genome-sequencing-diagnosing-rare-diseases
Press release - 18/11/2021 Overcoming resistance to cancer treatment: bone and soft tissue tumors in adolescents as a model system Treatment resistance is a central problem in the treatment of cancer. Bone and soft tissue tumors – known as sarcomas – in adolescents and young adults often stop responding to treatment too. This is because cancer cells develop a large number of new characteristics as the disease progresses and often become resistant to drugs that were originally effective.https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-cancer-treatment-bone-and-soft-tissue-tumors-adolescents-model-system
Press release - 06/02/2023 Fewer side effects thanks to personalised medicine Patients have 30 percent fewer serious side effects when medication doses are tailored to their genetic profile. This is what an international research consortium has found out, including the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology at the Bosch Health Campus. With an individual DNA medication pass, as used in the study, treatments can be made more effective and safer in the future.https://www.gesundheitsindustrie-bw.de/en/article/press-release/weniger-nebenwirkungen-dank-personalisierter-medizin
Dossier - 11/10/2023 The quantum revolution in the healthcare industry From ultra-fast quantum computers to highly sensitive sensors - quantum technologies could take medicine a giant step forward. Possible areas of application range from drug development and early cancer detection to reading brain waves to control prostheses or exoskeletons. The German state of Baden-Württemberg plays a key role in the development of sensors in particular.https://www.gesundheitsindustrie-bw.de/en/article/dossier/The-quantum-revolution-in-the-healthcare-industry
CeGat GmbH - 06/08/2020 CeGaT: Specific coronavirus antibody test for all Have I perhaps already had COVID-19 in the past? This is a question many of us have been asking. Reliable tests that would provide the answer have simply not been available until now. However, the Tübingen-based biotech company CeGaT is now offering a coronavirus antibody test to anyone who wants one, thus answering this question with the highest probability currently possible. Response to the offer has been huge in the few weeks since the test…https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-specific-coronavirus-antibody-test-all
Article - 04/11/2020 Rapid coronavirus test delivers results in 43 minutes The Hahn-Schickard Institute and Spindiag GmbH in Freiburg im Breisgau have joined forces to develop a rapid test used at the point of care. The test takes just 43 minutes to show whether a patient is infected with the coronavirus SARS-CoV-2. The rapid test is expected to be given market approval in Germany and the EU during the final quarter of 2020.https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-coronavirus-test-delivers-results-43-minutes
Tumour organoids facilitate drug discovery - 20/07/2023 Drug screening for children with cancer using patient-specific miniature tumours Standard drugs often don’t work in children and adolescents with recurrent cancer. Researchers from the Hopp Children's Tumour Centre (KITZ) and the German Cancer Research Center (DKFZ) in Heidelberg have been looking to open up new therapy options for those affected, and have cultivated individual miniature tumours from biopsy samples to test the effectiveness of a variety of drugs within a few weeks.https://www.gesundheitsindustrie-bw.de/en/article/news/drug-screening-children-cancer-using-patient-specific-miniature-tumours
Press release - 23/05/2024 Predicting cancer risks on the basis of national health data Scientists from the German Cancer Research Center (DKFZ) and the European Bioinformatics Institute EMBL-EBI, Hinxton, UK, are using the Danish health registers to predict individual risks for 20 different types of cancer with a high degree of accuracy. The prediction model can also be transferred to other healthcare systems. https://www.gesundheitsindustrie-bw.de/en/article/press-release/predicting-cancer-risks-basis-national-health-data
Press release - 22/08/2024 Validated targets for personalized cancer immunotherapy Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/validated-targets-personalized-cancer-immunotherapy
Press release - 26/11/2024 Collaborative research centres on kidney and brain prolonged On 25 November, the German Research Foundation (DFG) announced the continued funding of two existing Collaborative Research Centres (CRC) at the University of Freiburg’s Faculty of Medicine. In CRC 1453 Nephrogenetics (NephGen), doctors and researchers are using genetic information to search for mechanisms underlying kidney diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/collaborative-research-centres-kidney-and-brain-prolonged
New edition - 24/05/2019 Tumour metastasis Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.https://www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
Article - 17/03/2021 Epigenetic switches in bacteria as biosensors The analysis of pathogen biomarkers and biomarkers for the diagnosis of diseases can be crucial for health. However, the detection of pathogens and diseases depends on a sensitive and reliable method that delivers rapid results. Biosensors have such properties. Researchers at the Institute of Biochemistry and Technical Biochemistry (IBTB) at Stuttgart University have constructed an epigenetic circuit composed of plasmids that might make it…https://www.gesundheitsindustrie-bw.de/en/article/news/epigenetic-switches-bacteria-biosensors